Supermarket retailers are quickly adjusting their stomach remedy schematics as Tagamet HB, the second product in the fast emerging H2 antagonist segment, goes from prescription to over-the-counter early this fall. With Pepcid AC (Johnson & Johnson/Merck Pharmaceuticals, Fort Washington, Pa.) on the shelves since June, Zantac (Glaxo Wellcome, London) slated for conversion within the next year and Axid (Whitehall-Robins, Madison, N.J.) under review by the Food and Drug Administration for ...

REGISTER TO VIEW THIS ARTICLE - Register for a Free Account

Why Register for FREE?

Registering for content on Supermarket News will give you INSTANT access to invaluable articles and media content that industry professionals rely on. You will have access to our special reports, feature articles, and industry analysis. It’s FREE, easy and quick.  What are you waiting for! In addition you will also receive a complimentary copy of SN's salary survey sent to you by email.
 

Click here to read the FAQ page if you have any questions (opens in a new window)
 

Attention Paid Print Subscribers:  While you have already been granted free access to SN we ask that you register now. We promise it will only take a few minutes! Or visit your profile and add your print magazine account number and zip code.

Already registered? here.